RCUS
RCUS clinical trials: Arcus Biosciences, Inc.
Every trial on ClinicalTrials.gov where Arcus Biosciences, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 56
- Trials linked
- 32
- As lead sponsor
- 24
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
RCUS on the catalyst calendar · RCUS registry changes
- Primary completion Mar 2029Sponsor estimatePhase 1NCT05536141A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsArcus Biosciences, Inc. · Clear Cell Renal Cell CarcinomaRecruitingRCUSLeadSMMTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2028Sponsor estimatePhase 3NCT07011719Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaArcus Biosciences, Inc. · Metastatic Clear Cell Renal Cell CarcinomaRecruitingRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2030Sponsor estimatePhase 3NCT06608927Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaArcus Biosciences, Inc. · Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 1NCT05891171Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersArcus Biosciences, Inc. · Advanced CancerActive, not recruitingRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 7, 2026ActualPhase 2NCT05329766A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper...Arcus Biosciences, Inc. · Gastrointestinal Tract MalignanciesCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 17, 2026ActualPhase 2NCT04736173Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerArcus Biosciences, Inc. · Non Small Cell Lung CancerCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2026ActualPhase 1NCT06120075A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced MalignanciesArcus Biosciences, Inc. · Advanced CancerCompletedRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2026ActualPhase 1NCT04104672A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal MalignanciesArcus Biosciences, Inc. · Advanced Pancreatic CancerCompletedRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 1NCT07751250Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal...Arcus Biosciences, Inc. · Healthy ParticipantsRecruitingRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 28, 2026ActualPhase 3NCT05568095A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper...Arcus Biosciences, Inc. · Advanced Upper Gastrointestinal Tract AdenocarcinomaCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07662057A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy ParticipantsArcus Biosciences, Inc. · Healthy VolunteersRecruitingRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 3, 2026ActualPhase 1NCT07641881A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult ParticipantsArcus Biosciences, Inc. · Healthy ParticipantsCompletedRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 9, 2025ActualPhase 2NCT04262856Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerArcus Biosciences, Inc. · Non Small Cell Lung CancerCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 6, 2026ActualPhase 1NCT07364214Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)Arcus Biosciences, Inc. · Healthy ParticipantsCompletedRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 18, 2025ActualPhase 1NCT06919991Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)Arcus Biosciences, Inc. · Healthy ParticipantsCompletedRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2025ActualPhase 1/Phase 2NCT04660812An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With...Arcus Biosciences, Inc. · Metastatic Colorectal CancerCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 25, 2025ActualPhase 1NCT04772989A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesArcus Biosciences, Inc. · Advanced Solid TumorCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2024ActualPhase 1/Phase 2NCT04381832Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerArcus Biosciences, Inc. · Prostatic Neoplasms, Castration-ResistantCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 23, 2025ActualPhase 1NCT03628677A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced MalignanciesArcus Biosciences, Inc. · Solid Tumor, Unspecified, AdultCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 18, 2024ActualPhase 1NCT03846310A Study to Evaluate Immunotherapy Combinations in Participants With Lung CancerArcus Biosciences, Inc. · Non Small Cell Lung Cancer MetastaticCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2023ActualPhase 1NCT05999513A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult VolunteersArcus Biosciences, Inc. · Healthy ParticipantsCompletedRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2023ActualPhase 1NCT05117554Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy VolunteersArcus Biosciences, Inc. · Healthy ParticipantsCompletedRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2024ActualPhase 1NCT04087018Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid TumorsArcus Biosciences, Inc. · Advanced Solid TumorsCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 23, 2024ActualPhase 1NCT06004921A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy VolunteersArcus Biosciences, Inc. · CancerCompletedRCUSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2022ActualPhase 1NCT05411146A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of...Arcus Biosciences, Inc. · Healthy ParticipantsCompletedRCUSLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 31 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner